The announcement about the testing comes as the outbreak in West Africa grows. The World Health Organizations says it could have infected more than 20,000 people.
The Wall Street Journal: Testing On Experimental Ebola Vaccine To Begin in U.S.
The National Institutes of Health said Thursday it will begin testing an experimental Ebola vaccine in humans next week, accelerating research as an epidemic caused by the deadly virus continues to ravage West Africa (McKay, 8/28).
Los Angeles Times: NIH To Launch Ebola Vaccine Trials In Humans
The National Institutes of Health has announced the first clinical trial of a vaccine to protect healthy people from infection by the Ebola virus, which is responsible for an estimated 1,550 deaths throughout West Africa. NIH director Francis Collins on Thursday called the human safety trials, which are to start next week in Bethesda, Md., the latest in a series of the "extraordinary measures to accelerate the pace of vaccine clinical trials" for the public health emergency in Africa (Healy, 8/28).
The Hill: NIH Accelerates Ebola Vaccine Development
The government is speeding up its development of several potential Ebola vaccines in response to the largest ever outbreak of the virus in West Africa. The National Institutes of Health (NIH) confirmed Thursday that it will start testing a vaccine candidate on humans next week for the first time ever (Viebeck, 8/28).
The New York Times: Ebola Could Strike 20,000, World Health Agency Says
The World Health Organization said on Thursday that the Ebola epidemic was still accelerating and could afflict more than 20,000 people -- almost seven times the current number of reported cases -- before it could be brought under control (Cumming-Bruce and Cowell, 8/28).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.